In patients with isocitrate dehydrogenase (IDH) mutant gliomas, post-surgery contrast enhancement occurred in 56% of cases, of which 28% were pseudoprogression and 55% were actual tumor progression [35]. Here, IDH3A is linked to central nervous system cancer.